We believe that artificial viruses are the next generation of therapeutic modalities. To realize this, we have developed the 1st artificial virus platform. It enables us to design, build, and test fully synthetic (or artificial) viruses very fast and efficiently. Our initial focus is on cancer therapies. Our first patients will be dogs, later humans. We are based in New York City.